Richard Rosenzweig is a strategic and business-minded legal executive with broad commercial focus, diverse business leadership and a 20-year history with global health care companies. Most recently a corporate officer at C. R. Bard, Rich is known for providing exceptional guidance to frame and implement business and legal strategy at public companies while delivering excellent results in transactions and litigation/disputes. He has deep experience counseling company boards, including Audit, Finance, Governance and Compensation committees. He is well-versed in compensation matters and management of SEC and regulatory compliance issues. He has served as a key advisor and leader on mergers and acquisitions, integrations, and other corporate initiatives, including the $24.7B sale of Bard to Becton Dickinson.
Across his career, Rich has developed a reputation as a strong leader with a collaborative style. He has extensive experience establishing and managing legal teams to support and protect growth, and a history of recruiting and retaining talent.
Over more than 10½ years at C. R. Bard, Rich managed a broad portfolio that touched all parts of the medical device business, including SEC compliance and financing transactions, M&A and business development, litigation, operations, clinical affairs, sales and marketing, investor relations, executive compensation, and licensing and antitrust issues. He was elected as a corporate officer (Vice President, Law & Assistant Secretary) in 2010 and was a member of the Corporate Management Committee. He closed more than 75 deals, including the acquisition of four public companies and the first peripheral vascular drug-coated balloon (Lutonix®). In 2017, he partnered with the CFO, General Counsel and Controller to lead the sale to Becton Dickinson. He previously served as Associate General Counsel (2007-2010).
Prior to Bard, Rich was Senior Vice President, General Counsel and Secretary at Phibro Animal Health Corporation (2006-2007), responsible for all legal affairs. He supervised compliance with SEC rules and regulations, advised on regulatory matters (including FDA), managed a significant litigation portfolio and provided strategic direction for environmental matters, including oversight of the environmental, health and safety function. Rich also led the public-to-private restructuring and refinancing of the company.
Rich spent 3½ years as SVP, General Counsel & Secretary at IMPATH, Inc., a publicly-traded laboratory that provided advanced cancer pathology, drug discovery and development services. He led major strategic and business development activities, M&A, investment banking and corporate finance initiatives, and the company’s compliance function. Rich managed the strategic planning and development function of the company’s software division, was responsible for overseeing human resources and investor relations functions, and assumed interim responsibility for managing the company’s clinical trial business. He co-managed, along with the CEO, the restructuring of the company. Later, he jointly led with the CEO the Chapter 11 restructuring and asset sales, including the sale of the lab to Genzyme.
Rich also held positions as Director, Worldwide Licensing & Acquisitions at Johnson & Johnson and Corporate Associate at various law firms in New York.
Rich has a JD from Boston University School of Law and a BA in Psychology from Brandeis University. He is an Advisor to TEAMFund, an impact investment fund co-founded by the former CEO of Bard and is Vice Chair and Chair-Elect of the Director’s Leadership Council of the Rutgers Cancer Institute of New Jersey. He lives in New Jersey with his wife, Suzy, and twin girls, who are freshmen in college.